Program
tezepelumab
Also written as “Tezepelumab”, “Experimental: Tezepelumab” and “MEDI9929”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic · Nasal Polyps · Rhinosinusitis, led by 3 companies.
Drug pageTezepelumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 288 open or running | phase 4since Mar 17, 2022 | Jul 30, 2013 | Jan 13, 2027phase 3 · NCT06706817 |
| Amgenits history only | 50 open or running | phase 2since Jan 10, 2019 | Sep 18, 2008 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | Dec 2028phase 3 · NCT07302516 |
Also a collaborator on its studies: Fortrea and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qilu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named tezepelumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, MEDI9929
- Dec 11, 2025First study: phase 3 study in AsthmaFirst studyNCT07302516 · 636 planned
Ahead
- Dec 2028Primary completion: phase 3 study in AsthmaNCT07302516
TargetBeta
“Thymic stromal lymphopoietin inhibitor; Thymic stromal lymphopoietin inhibitor”ChEMBL 37, by rule
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
The one study Qilu Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07302516Asthma | 3 | Not yet recruiting | Dec 2028 | 636 |
How it is read
Names in the registry
- “Tezepelumab”, 23 entries
- “Experimental: Tezepelumab”, 4 entries
- “MEDI9929”, 2 entries
- “tezepelumab (Arm1&Arm2)”, 1 entry
- “Tezepelumab Dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 20 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Dermatitis, Atopic, 3 studies
- Nasal Polyps, 2 studies
- Rhinosinusitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.